{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:52:01Z","timestamp":1780339921234,"version":"3.54.1"},"reference-count":0,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Anthracyclines and taxanes have historically constituted the backbone of chemotherapy regimens for patients with breast cancer positive for the human epidermal growth factor receptor 2 (HER2). For a subset of patients who categorically refuse alopecia, or for those with a contraindication to those drugs, there is an urgent need to define alternative regimens. Here, we report our institutional experience with trastuzumab and vinorelbine (TV), a combination with good clinical activity and a good side effect profile for patients with HER2-positive breast cancer. Methods: In a retrospective analysis, outcomes data were extracted for patients receiving TV as their only chemotherapy in the non-metastatic setting at the Jewish General Hospital. For the most part, TV was administered weekly for 6 months, followed by trastuzumab for 6 months. Results: The analysis identified 46 patients (mean age: 64 years) who received TV between 2003 and 2012 (n = 36 adjuvant, n = 10 neoadjuvant). Of the patients in the adjuvant group, 81% had stage i disease. In the neoadjuvant group, 3 patients experienced a complete pathologic response. Only 1 patient experienced local recurrence after a short course (3 months) of adjuvant TV. Overall survival and breast cancer\u2013specific survival were 94% and 98% respectively at a median 5 years of follow-up. Febrile neutropenia\u2013induced sepsis resulted in the death of 1 patient with significant medical comorbidities; 2 other patients died of comorbidities unrelated to their cancer or treatment. Grades 3 or 4 adverse events included neutropenia (23%), febrile neutropenia (10%), fatigue (2%), and anemia (2%). Conclusions: For patients with non-metastatic breast cancer refusing alopecia, or for patients who are not candidates for standard chemotherapy, TV is a reasonable alternative to standard adjuvant chemotherapy.<\/jats:p>","DOI":"10.3747\/co.21.2069","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T17:43:06Z","timestamp":1412876586000},"page":"723-727","source":"Crossref","is-referenced-by-count":7,"title":["The Trastuzumab and Vinorelbine Combination: An Alternative to Taxane-Based Chemotherapy for Early-Stage and Locally Advanced HER2-Positive Breast Cancer"],"prefix":"10.3390","volume":"21","author":[{"given":"K.","family":"Esfahani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Panasci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2014,10,1]]},"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/21\/5\/2069\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T07:59:36Z","timestamp":1613721576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/21\/5\/2069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["co.21.2069"],"URL":"https:\/\/doi.org\/10.3747\/co.21.2069","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}